ClinicalTrials.gg
CompletedNCT07090655Updated Jul 30, 2026

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

An Early Phase 1 interventional study of Budoprutug and Placebo in Healthy Volunteers, sponsored by Climb Bio, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Climb Bio, Inc. · Early Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main objective is to assess the safety and tolerability of subcutaneous and intravenous injection forms of budoprutug in healthy volunteers.

Read the detailed description

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of budoprutug administered subcutaneously (SC) in adult normal healthy volunteers (NHVs). To assess the bioavailability of the SC formulation, one cohort will receive a single intravenous (IV) dose of budoprutug. Approximately 38 participants will be enrolled across four dose cohorts, including three SC dose levels and one IV comparator group.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • healthy
  • volunteer
03

In context

Lead sponsor

Climb Bio, Inc. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males and females aged 18-60 years
  • (BMI) between 18 and 32 kg/m² and weight between 45 and 110 kg
  • Clinically normal medical history, physical exam, , and laboratory results (or abnormalities deemed not )
  • Willing and able to comply with study procedures and provide
  • Women of must use highly effective and have negative pregnancy tests
  • Men must use contraception and refrain from sperm donation for 6 months post-dose
  • Completion of a 2-dose primary COVID-19 vaccination series and at least 1 booster dose, as well as influenza vaccination (within 12 months)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with drugs within 30 days or 5 half-lives
  • History of hypogammaglobulinemia or significant allergic reactions
  • Recent infections, including serious local/systemic infections or opportunistic infections
  • Positive tests for , /C, syphilis, or tuberculosis
  • Use of tobacco (>2 cigarettes/day), alcohol abuse, or recreational drugs
  • Recent (within 21 days) or any non-live vaccine (within 14 days)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Budoprutug

    Subcutaneous (SC) injection or IV administration of budoprutug

    Drug: Budoprutug

  • Placebo comparator
    Placebo

    Placebo solution to be administered at a matching volume

    Drug: Placebo

Interventions

  • Subcutaneous or IV administration

    Also known as: TNT119

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Single Ascending Doses of budoprutug in Healthy Participants

    Incidence of treatment-emergent adverse events

    Time frame: Day 57

  2. Incidence of infusion-related reactions (IRRs) for IV administration

    Number of infusion-related reactions

    Time frame: Day 57

  3. Incidence of injection site reactions (ISRs) for SC administration

    Number of injection site reactions

    Time frame: Day 57

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Measurement of the maximum observed plasma concentration.

    Time frame: Day 57

  2. Time to Maximum Observed Concentration (Tmax)

    Measurement of the time to maximum observed concentration.

    Time frame: Day 57

  3. Area Under the Curve (AUC)

    Measurement of the area under the drug concentration-time curve.

    Time frame: Day 57

  4. Terminal Half-Life (T1/2)

    Measurement of the terminal half-life in days.

    Time frame: Day 57

  5. Bioavailability (F)

    Relative absorption of SC vs IV budoprutug (%).

    Time frame: Day 57

07

Study locations

1 site
  • Nucleus Network Brisbane
    Brisbane, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Apr 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Jul 29, 2025
StartActual
Aug 11, 2025
Primary completionActual
Apr 7, 2026
CompletionActual
Apr 7, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07090655
Lead sponsor
Climb Bio, Inc.
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Aug 11, 2025
Primary completion
Apr 7, 2026
Completion
Apr 7, 2026
Last update
Jul 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budoprutug

Start the discussion